Current Drug Therapy

Scope & Guideline

Navigating the Evolving Landscape of Drug Therapy

Introduction

Welcome to the Current Drug Therapy information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of Current Drug Therapy, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN1574-8855
PublisherBENTHAM SCIENCE PUBL LTD
Support Open AccessNo
CountryUnited Arab Emirates
TypeJournal
Convergefrom 2007 to 2024
AbbreviationCURR DRUG THER / Curr. Drug Ther.
Frequency2 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressEXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES

Aims and Scopes

Current Drug Therapy focuses on advancing knowledge in the field of pharmacology and drug therapy through innovative research, reviews, and critical analyses. The journal emphasizes the significance of new drug therapies, delivery systems, and the therapeutic potential of various compounds across diverse medical conditions.
  1. Pharmacological Innovations:
    The journal consistently explores new pharmacological agents and their therapeutic applications, emphasizing innovative drug therapies, including both synthetic and natural compounds.
  2. Drug Delivery Systems:
    A significant focus is placed on the development and optimization of various drug delivery systems, including nanotechnology-based approaches, to enhance the efficacy and bioavailability of therapeutic agents.
  3. Clinical Applications and Reviews:
    The journal publishes comprehensive reviews and clinical studies that analyze the effectiveness and safety of drug therapies across a broad range of medical conditions, including cancer, diabetes, and infectious diseases.
  4. Natural Products and Herbal Medicines:
    There is a notable emphasis on the pharmacological potential of natural products and herbal medicines, highlighting their roles in modern therapeutic regimens.
  5. Emerging Therapeutic Strategies:
    Current Drug Therapy addresses novel therapeutic strategies, including the use of combination therapies, repurposing existing drugs, and exploring the mechanisms of action of various therapeutic agents.
The journal has reflected an evolving focus in recent years, highlighting several emerging themes that are gaining traction in the realm of drug therapy and pharmacology. These trending scopes indicate the dynamic nature of research within the field.
  1. Nanotechnology in Drug Delivery:
    There is a significant increase in research related to nanotechnology-based drug delivery systems, showcasing their potential to enhance the efficacy and precision of therapeutic interventions.
  2. Personalized Medicine:
    Emerging themes around personalized medicine and precision therapy are gaining momentum, reflecting the need for tailored treatment approaches based on individual patient profiles.
  3. Research on Obesity and Metabolic Disorders:
    Recent publications have increasingly addressed obesity and related metabolic disorders, emphasizing the development of novel treatments and therapeutic strategies.
  4. Integrative and Complementary Approaches:
    The journal is witnessing a rise in integrative and complementary approaches to treatment, combining traditional practices with modern pharmacotherapy.
  5. Artificial Intelligence and Machine Learning in Drug Development:
    Research utilizing artificial intelligence and machine learning techniques for drug discovery and development is becoming more prevalent, indicating a trend towards data-driven approaches in pharmacology.

Declining or Waning

While Current Drug Therapy continues to thrive in various research areas, some themes have shown a decline in recent publications. These waning scopes may reflect shifting research priorities or a saturation of the existing literature.
  1. Conventional Drug Therapies:
    There is a noticeable decrease in publications focusing solely on conventional drug therapies, as the journal shifts towards more innovative and advanced therapeutic approaches.
  2. Traditional Medicine Approaches:
    Research related to traditional medicine approaches appears to be declining, potentially as a result of the increasing focus on evidence-based and modern therapeutic strategies.
  3. Basic Pharmacology Studies:
    Basic pharmacology studies, while still relevant, have seen a reduction in frequency, suggesting a trend towards applied research with direct clinical implications.
  4. Single-Agent Studies:
    The trend of publishing studies that focus on single-agent drug therapies is waning, as the field increasingly favors combination therapies or multi-targeted approaches.
  5. Mechanistic Studies of Well-Established Drugs:
    There has been a decrease in the publication of mechanistic studies involving well-established drugs, possibly due to a shift in interest towards novel compounds and therapies.

Similar Journals

MEDICINE

Advancing medical knowledge for a healthier tomorrow.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0025-7974Frequency: 52 issues/year

MEDICINE, published by Lippincott Williams & Wilkins, is an esteemed open access journal in the field of general medicine, holding a significant position with a Scopus rank of #190 out of 636 in its category (2023), placing it in the 70th percentile. Since its inception in 1922, MEDICINE has been a vital platform for researchers, professionals, and students to disseminate groundbreaking findings and advancements in the medical field. With the transition to open access in 2014, the journal ensures that valuable research is readily available to a global audience, fostering collaboration and innovation across diverse medical disciplines. Its current impact factor and influence in the miscellaneous medicine category (Q3) reflect its commitment to supporting rigorous peer-review processes and promoting scholarly excellence. Located in Philadelphia, PA, the journal covers a wide range of topics, making it a crucial resource for those dedicated to the betterment of healthcare and medical education.

FUNDAMENTAL & CLINICAL PHARMACOLOGY

Empowering healthcare through innovative pharmacological research.
Publisher: WILEYISSN: 0767-3981Frequency: 6 issues/year

FUNDAMENTAL & CLINICAL PHARMACOLOGY is a distinguished journal dedicated to advancing the fields of pharmacology and clinical medicine. Published by WILEY, this journal serves as a pivotal platform for researchers, healthcare professionals, and students alike to disseminate innovative research findings and clinical applications. With an impressive history spanning from 1987 to 2024, it has consistently maintained its relevance in the scientific community, evidenced by its Q2 quartile ranking in both Pharmacology and Pharmacology (medical) categories for 2023. The journal's diverse publication range, which includes original research articles, reviews, and clinical studies, helps bridge the gap between fundamental research and practical application in healthcare settings. Although it does not offer open access, its rigorous peer-review process ensures that published content meets the highest scholarly standards, making it a vital resource for those aiming to stay at the forefront of pharmacological sciences.

CURRENT DRUG TARGETS

Connecting Researchers to the Future of Medicine
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1389-4501Frequency: 16 issues/year

CURRENT DRUG TARGETS is a leading peer-reviewed journal dedicated to advancements in the fields of Clinical Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. Published by Bentham Science Publishers Ltd, this esteemed journal has solidified its position in the academic community with a 2023 Q2 ranking in several categories, highlighting its influence and relevance in drug research and development. With an ISSN of 1389-4501 and E-ISSN 1873-5592, CURRENT DRUG TARGETS facilitates the dissemination of high-quality articles that explore novel therapeutic strategies and drug design principles. Catered to researchers, professionals, and students, the journal has a commitment to advancing knowledge while addressing contemporary challenges in pharmacological sciences. As it converges from 2000 to 2024, CURRENT DRUG TARGETS remains a vital resource in understanding the complexities of drug action and interaction, making it indispensable for anyone pursuing cutting-edge research in related disciplines.

Drug Design Development and Therapy

Elevating Drug Discovery with High-Impact Research
Publisher: DOVE MEDICAL PRESS LTDISSN: 1177-8881Frequency: 1 issue/year

Drug Design Development and Therapy is a premier open-access journal published by DOVE MEDICAL PRESS LTD, dedicated to advancing the fields of drug discovery, pharmaceutical science, and pharmacology. With an impressive Q1 ranking in its categories as of 2023, this journal is recognized for its significant contributions to the understanding of drug design and therapeutic innovations, making it an invaluable resource for researchers, professionals, and students alike. Established in 2007 and committed to open-access since 2008, the journal provides an inclusive platform for disseminating high-quality research from around the globe. With a robust impact factor and remarkable Scopus rankings, including a 24th place in Pharmaceutical Science and a 48th place in Pharmacology, it reflects a strong percentile performance, ensuring that published articles reach and impact a wide audience. By fostering the exchange of cutting-edge information on drug development and delivery systems, Drug Design Development and Therapy continues to play a crucial role in the ongoing battle against disease, promoting innovative approaches to therapeutic solutions and enhancing patient care.

Current Molecular Pharmacology

Advancing the Frontiers of Pharmacology
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1874-4672Frequency: 7 issues/year

Current Molecular Pharmacology, published by Bentham Science Publishers, is a prominent journal focused on the dynamic fields of pharmacology, drug discovery, and molecular medicine. With an ISSN of 1874-4672 and an E-ISSN of 1874-4702, this journal aims to disseminate cutting-edge research and review articles that showcase innovative methodologies and groundbreaking findings from 2008 through 2024. Holding a respectable Q3 category ranking in Drug Discovery, Molecular Medicine, and Pharmacology for 2023, Current Molecular Pharmacology serves as an essential platform for both established researchers and emerging scholars to share their insights. The journal is indexed in Scopus with its relevant ranks catering to pharmacology and molecular biology, ensuring it reaches a wide array of professionals, researchers, and students in the field. As a contributor to advancing pharmacological sciences, this journal provides invaluable access to the latest advancements and fosters ongoing dialogue in molecular pharmacology, positioning itself as a key resource in the exploration of therapeutic agents and their interactions.

Anti-Cancer Agents in Medicinal Chemistry

Driving breakthroughs in anti-cancer agent development.
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1871-5206Frequency: 10 issues/year

Anti-Cancer Agents in Medicinal Chemistry is a pivotal journal in the realm of cancer research, published by Bentham Science Publishers in the United Arab Emirates. With an ISSN of 1871-5206 and an E-ISSN of 1875-5992, this esteemed journal has been disseminating high-quality research since its inception in 2006, and is set to continue through 2024. The journal is categorized in the third quartile (Q3) across key areas including Cancer Research, Molecular Medicine, and Pharmacology, highlighting its essential role in providing valuable insights to the scientific community. Despite its open-access status being unspecified, researchers benefit from the rigorous peer-review process ensuring the publication of significant advancements. The journal ranks well within Scopus, particularly in the fields of Pharmacology and Cancer Research, which positions it as a notable resource for professionals, students, and researchers aiming to deepen their knowledge in anti-cancer strategies. Through its comprehensive scope, the journal aims to bridge the gap between medicinal chemistry and clinical applications, making it an indispensable tool for those dedicated to advancing cancer therapeutics.

Advances in Pharmacology and Pharmacy

Pioneering Discoveries in Drug Development
Publisher: HORIZON RESEARCH PUBLISHINGISSN: 2332-0036Frequency: 3 issues/year

Advances in Pharmacology and Pharmacy is a pioneering journal devoted to the dissemination of cutting-edge research in the fields of pharmacology and pharmaceutical sciences. Published by Horizon Research Publishing, this peer-reviewed journal boasts a commitment to advancing knowledge and innovation, making it an essential resource for researchers, industry professionals, and students alike. With an ISSN of 2332-0036 and an E-ISSN of 2332-0044, it provides a platform for high-quality research articles that explore new therapeutic approaches, drug development strategies, and the regulatory aspects of pharmaceutical science. Although currently lacking a formal impact factor, the journal's emphasis on open access ensures that articles are widely available, promoting the sharing of valuable insights and collaborative efforts in the scientific community. Located at 506 N Garfield Ave, Ste 210, Alhambra, CA 91801, the journal welcomes contributions from diverse areas within pharmacology and pharmacy, reinforcing its significance as a vital resource in the ever-evolving landscape of pharmaceutical research.

ACTA POLONIAE PHARMACEUTICA

Advancing Pharmaceutical Knowledge Since 1951
Publisher: POLSKIE TOWARZYSTWO FARMACEUTYCZNEISSN: 0001-6837Frequency: 4 issues/year

ACTA POLONIAE PHARMACEUTICA is a well-established peer-reviewed journal published by Polskie Towarzystwo Farmaceutyczne, dedicated to the field of pharmaceutical sciences and pharmacology. With a rich history dating back to 1951, this journal serves as a vital platform for disseminating cutting-edge research and developments in pharmaceutical technology, drug development, and therapeutic therapies. Although it currently operates under a subscription model, its commitment to scientific rigor has earned it a respectable impact factor, placing it in the Q3 and Q4 quartiles respectively for Pharmaceutical Science and Pharmacology as of 2023. Researchers and practitioners alike will find value in its comprehensive coverage of essential topics, as well as its diverse range of contributions from both established and emerging scholars in the field. With its address located in the heart of Warsaw, Poland, ACTA POLONIAE PHARMACEUTICA aims to further bridge the gap between academia and industry, paving the way for innovation in drug discovery and therapeutic applications.

SCIENTIA PHARMACEUTICA

Empowering researchers with open access to cutting-edge findings.
Publisher: MDPIISSN: Frequency: 4 issues/year

SCIENTIA PHARMACEUTICA, published by MDPI in Switzerland, is a leading open access journal dedicated to advancing the field of pharmaceutical sciences since 2006. With a focus on pharmacology, toxicology, and pharmaceutics, this journal plays a pivotal role in disseminating high-quality research and innovative findings. It boasts an impressive impact factor and is ranked in the second quartile (Q2) for Pharmaceutical Science, signifying its influence within the academic community, aided by a Scopus ranking of 74 out of 183 journals in the same category. SCIENTIA PHARMACEUTICA invites original research articles, reviews, and notes that contribute to the understanding and development of pharmaceutical science, making it an essential resource for researchers, professionals, and students alike seeking to stay at the forefront of this continuously evolving field. For those interested in broadening their knowledge and sharing insights, the journal ensures wide accessibility, supporting the open access model for maximum outreach.

Research in Pharmaceutical Sciences

Navigating the Complexities of Drug Safety
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 1735-5362Frequency: 6 issues/year

Research in Pharmaceutical Sciences is a premier, peer-reviewed journal published by Wolters Kluwer Medknow Publications, dedicated to advancing the field of pharmacology, toxicology, and pharmaceutics. With an impact factor that positions it in the second quartile of its category (Q2) and a respectable rank of 23 out of 80 in Scopus, this journal serves as an essential platform for researchers, professionals, and students alike, providing open access since 2015 to a wealth of pioneering studies and comprehensive reviews. Based in Mumbai, India, the journal encompasses a diverse range of topics within the pharmaceutical sciences, offering insights that address both theoretical and practical challenges in drug development and safety. As it converges from 2009 to 2024, Research in Pharmaceutical Sciences continues to be a vital source of knowledge, promoting innovation and fostering collaboration within the global scientific community.